logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals

Small Cap•600 Employees•IPO 2015
Current Price
₹18.88
-0.85 (-4.31%)Updated
NSE :BALAXI
BSE :
Sector :Health Care Providers & Services
Today's Range
₹18.50
₹18.88
union icon
₹20.00
52 Week Range
52W Low₹19.60
52W High₹76.10
₹18.88
union icon
Downside-3.67%
Upside303.07%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹115.11 Cr
Market Cap
Total market value of company
P/E Ratio
12.27
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
1.01
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹1.72
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
3.75%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
13.00%
ROCE
Return on Capital Employed. >15% is good
Net Margin
4.45%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-5.73%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
45.01%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
7.80%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-95.50%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.23
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹41.98
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
66.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Healthy financial structure with low debt-to-equity ratio of 0.23.
  • •P/E ratio of 12.30 appears attractively valued versus industry peers.

Weaknesses

5 points
  • •Latest quarterly net profit declined -95.50% to 0.29 Cr, raising concerns.
  • •ROCE at 13.00% is notably lower than major pharmaceutical peers.

Opportunities

5 points
  • •Broader Pharmaceuticals and Healthcare sector offers inherent growth opportunities globally.
  • •Low P/E of 12.30 suggests potential for significant valuation re-rating.

Threats

5 points
  • •Intense competition from larger, established players challenges market share, pricing.
  • •Adverse changes in government regulations, drug pricing policies could impact profitability.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹22.75+₹3.87+20.52%
R3₹21.25+₹2.37+12.57%
R2₹20.63+₹1.75+9.25%
R1₹19.75+₹0.87+4.63%
PIVOT₹19.130.251.31%
CURRENT₹18.88--
S1₹15.25-₹3.63-19.21%
S2₹16.75-₹2.13-11.26%
S3₹17.63-₹1.25-6.64%
S4₹18.25-₹0.63-3.32%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.04L
(02 Mar 2026)
-41.1% vs avg
Delivery %
69.7%
(02 Mar 2026)
-3.1% vs avg
Avg Volume (20D)
1.76L
(03 Feb - 02 Mar)
20-day average
Avg Delivery %
72.9%
(03 Feb - 02 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Entero Healthcare Solutions Ltd
4,823.41 ₹ Cr
Best Profit Growth
Entero Healthcare Solutions Ltd
38.40 %
Highest Dividend Yield
Entero Healthcare Solutions Ltd
0.00 %

Peer Comparison

Company Name
ENTERO
Entero Healthcare Solutions Ltd

About

BALAXI

Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited is an international wholesale distributor of a diverse range of products, primarily focused on serving markets in Africa, the Caribbean Islands, and Latin America. The company's core business centers around the pharmaceutical sector, where it offers a broad selection of medications targeting various therapeutic areas. This includes crucial treatments for common ailments and infections such as antibiotics, analgesics (painkillers), and anti-malarial drugs, alongside other pharmaceutical products.

Beyond pharmaceuticals, Balaxi Pharmaceuticals Limited extends its distribution network to encompass fast-moving consumer goods (FMCG) and builders' hardware. In the FMCG realm, the company's offerings include essential items such as biscuits and toothpaste. The inclusion of these products demonstrates a strategy to diversify its portfolio and cater to a broader consumer base in the regions it serves. This multi-product approach likely allows the company to leverage its established distribution network for greater efficiency and market penetration.

Established in 1942 and headquartered in Hyderabad, India, Balaxi Pharmaceuticals Limited has a long history in international trade. The company operates as a subsidiary of Balaxi Overseas Private Limited, indicating a larger corporate structure with potentially broader resources and strategic direction. The name change from Balaxi Ventures Limited to Balaxi Pharmaceuticals Limited in October 2020 reflects a strategic focus on the pharmaceutical sector while maintaining its commitment to diversified product offerings within its established international markets.

In summary, Balaxi Pharmaceuticals Limited's business model is built upon a foundation of international wholesale distribution, skillfully navigating the complexities of supplying diverse product categories to various markets across Africa, the Caribbean, and Latin America. The company leverages its long-standing presence and established network to efficiently reach its target customer base, demonstrating a robust and adaptable business strategy in a dynamic international environment.

COMPANY FACTS - BALAXI

Registered Address

Plot No. 409, H. No. 8-2-293, Maps Towers,, 3rd Floor, Phase - III, Road No. 81, Jubilee Hills

Hyderabad

TELANGANA

IN

Tel: 914023555300

Website:https://balaxipharma.in/

Investor Relations:http://www.balaxipharma.in/investor-annual-report
Company Details

Group: Health Care Equipment & Services

Sector: Health Care

Industry: Health Care Providers & Services

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 600

IPO Date: 30/11/2015

MANAGEMENT - BALAXI

Mr. Ashish Maheshwari

Executive Chairman of the Board, Managing Director

Mr. Amol Mantri

Chief Financial Officer

Mr. Pranav Maheshwari

Senior Vice President - Business Development

Mr. Mohith Khandelwal

Compliance Officer, Company Secretary

Mr. Jignesh Shah

Finance Controller, Angola

Mr. Ram Chawla

Country Head, Angola

Mr. Bharat Jawarani

Sales Head, Dominican Republic

Mr. Manish Jumnani

Sales Head, Guatemala

Mr. Karan Kapoor

Head - Operations, Dominican Republic

Ms. Paridhi Maheshwari

Head - Alternate Channels

Mr. Laksh Shewakramani

Compliance Head, Angola

Mr. Pankaj Singh

Head - Operations, Guatemala

Investor Questions Answered

Balaxi Pharmaceuticals Ltd (BALAXI) Stock FAQs

Get answers to the most common questions about Balaxi Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹18.88. Today, the stock has declined by ₹0.85 (4.31%), trading in a range of ₹18.5 to ₹20. The stock opened at ₹20 with a trading volume of 1,03,745 shares.
Balaxi Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹115.11 crores, P/E ratio of 12.27, ROE of 3.75%, and ROCE of 13.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹76.1, while the 52-week low is ₹19.6. Currently trading at ₹18.88, the stock is -1.3% away from its 52-week low and 75.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Balaxi Pharmaceuticals Ltd stock at ₹18.88 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.27 and P/B ratio of N/A. Today's performance shows a loss of 4.31%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Balaxi Pharmaceuticals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹18.88, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Balaxi Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 12.27, P/B Ratio: N/A, ROE: 3.75%, ROCE: 13.00%, Dividend Yield: 0.00%, EPS: ₹1.72, Book Value: ₹41.98, Debt-to-Equity: 0.23, and Current Ratio: N/A. The company's market cap stands at ₹115.11 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Balaxi Pharmaceuticals Ltd stock opened at ₹20 and is currently trading at ₹18.88, showing a decline of ₹0.85 (4.31%). The intraday high is ₹20 and low is ₹18.5. The trading volume stands at 1,03,745 shares, indicating moderate market participation today.
Balaxi Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 12.27, which means investors are willing to pay ₹12.27 for every ₹1 of earnings. With an EPS of ₹1.72, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Balaxi Pharmaceuticals Ltd has a market capitalization of ₹115.11 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹18.88) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Balaxi Pharmaceuticals Ltd has a book value of ₹41.98 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹18.88, which is 55.0% below the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Balaxi Pharmaceuticals Ltd has a Return on Equity (ROE) of 3.75% and Return on Capital Employed (ROCE) of 13.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Balaxi Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Balaxi Pharmaceuticals Ltd has a debt-to-equity ratio of 0.23, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Balaxi Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹1.72, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹18.88 and P/E ratio of 12.27, investors are paying 12.27 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Balaxi Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Balaxi Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Balaxi Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (12.27), ROE (3.75%), debt-to-equity (0.23), and growth rates. 2) Technical Analysis - Check 52-week range (₹19.60 - ₹76.10), moving averages, and chart patterns. 3) Valuation - Compare current price (₹18.88) with book value (₹41.98) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Balaxi Pharmaceuticals Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹18.88 is 844x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Balaxi Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹19.60 - ₹76.10). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.23 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,03,745 shares. 5) Valuation Risk - P/E of 12.27 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Balaxi Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 12.27, ROE of 3.75%, market cap of ₹115.11 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.23), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Balaxi Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹18.88, with a 52-week range of ₹19.60 to ₹76.10. Based on fundamentals like P/E (12.27), ROE (3.75%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Balaxi Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹18.88. 2) Fundamental Deterioration - Declining ROE (currently 3.75%), increasing debt (D/E: 0.23), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Balaxi Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.